(一)F1000数据库简介 截止到2016年,F100的专家已由最初的1,0位 发展为由位3832 Faculty members和3465位 Associate Faculty Members共约7,00名来自全球 的生物医学专家团队 进入F1000数据库的论文,到目前为止已经接近 15万条记录,略占 Pubmed数据库文献的6%。 当我们在检索 Pubmed数据库时,F1000论文有 专门的提示
（一） F1000数据库简介 ➢ 截止到2016年，F1000的专家已由最初的1,000位 发展为由位3,832Faculty members和3,465位 Associate Faculty Members共约7,000名来自全球 的生物医学专家团队。 ➢ 进入F1000数据库的论文，到目前为止已经接近 15万条记录，略占PubMed 数据库文献的6‰。 ➢ 当我们在检索PubMed数据库时， F1000论文有 专门的提示
FIOoo FACULT YofIooo POST-PUBUICATION PEER REVIEW NCBI Resources C How To回 anhaitao3 My NCBI Sign Out US Natoral Litrary of Medicine Natonal institutes of Heath RSs Save search Advanced Display Settings: C Abstract Send to:回 THE LANCE FACULTY1000 See 1 citation found by title matching your search Lancet2012May19379291893901 Save items 1 dose-escalation trial Falchook GS, Long Gv, KurzrockR, Kim KE, Arkenau TH. Brown MP, Hamid O, Infante JR, Millward M, Pavlick AC, ODay S Blackman SC, Curtis CM, Lebowitz P Ma B. quellet D Kefford rF - Related citations in PubMed Department of Investigational Cancer Therapeutics, University of Texas MD And 可以方便地在 PubMed Inhibtion of mutated. activated BRAF in Abstract 检索结果中看到是否被 metastatic melanoma. N Engl J Med. 2010) KGROUND: Dabrafenib is an inhibitor of BraF kinase that is F1000推荐。 Dabrafenib in BRAF-mutated metastatic ish a recommended phase 2 dose in patients melanoma a multicentre, open-lab Lancet 2012 Survival in BraF v600-mutant advanced melanoma treated with vem( IN Engl J Med, 2012) METHODS: We undertook a phase 1 trial between May 27, 2009, and March 20, 2012, at eight study centres in Australia and the USA. Eligible Review PLX-4032, a small-molecule B-Raf patents had incurable solid tumours, were 18 years or older, and had adequate organ function. BRAF mutations were mandatory for inclusion later in inhibitor for the p(Curr Opin Investig Drugs. 2010) the study because of an absence of activity in patients with wild-type BRAF. We used an accelerated dose titration method, with the first dose cohort receiving 12 mg dabrafenib daily in a 21-day cycle. Once doses had been established, we expanded the cohorts to include up to 20 patients. On the Review Vemurafenib(PLX4032): an orally tumours including those with non-val6D0Glu mutations in three cohorts metastatic melanoma melanoma with untreated brain metastases, and non- melanoma solid tumours. This study is registered with ClinicalTrials. gov, number NCT00880321
可以方便地在PubMed 检索结果中看到是否被 F1000推荐
(二)F1000浏览 F1000主要包括以下3个部分,重点是F1000 Prime F1000 Research F1000 Workspace F1000Pime(主要内容)
（二） F1000浏览 F1000 主要包括以下3个部分，重点是F1000 Prime ➢ F1000 Research ➢ F1000 Workspace ➢ F1000 Prime（主要内容）
FIOoo Changing the way science is communicated powered by our Faculty of over 11,000 leading experts in Biology and Medicine. 團圈 DISCOVER WORK PUBLISH Powerful algorithms suggest A rich suite of tools help with n open science publishing articles relevant to your writing, collaborating, reference platform for life scientists research, with the best articles management and preparation offers immediate publicani highlighted as recommended for publishing in the journal of and transparent peer review. by F1000 Faculty Members. your choice Flo0o Prime FlooOWorkspace FIOOOResearch
PlooOPrime FIOCOResearch FlooOWorkspace Welcome Guest I Third Military Medical University CoPRime Article Recommendations Advanced AnONS I RANKINGS I F1000PRIME REPORTS I F1000 FACULTY I JOURNAL CLUBS I BLOG MyF1000 I SIGN IN V I REGISTEI Already Registered? sign in, You are three steps away from I enjoy and rely upon the many terrific features of the most effective personalized Faculty of 1000, but lately I have begun to worry that my F1000Prime Alerts know me better than I know myself. literature service Gerald F Joyce The Scripps Research Institute RY IT NOW Enter at least three keywords that represent your research interests (e. g dna immune bacterial NEXT FACULTYoflo0o is composed of 5,000 Faculty Members 月武 senior scientists and leading experts all areas of biology and medicine plus their associates The Faculty recommends the most important articles, rating them and providing short explanations for their selections 655300ge I find Faculty of 1000 useful for three main I really like the website! This is a tool that most reasons: identifying key papers in areas clinicians and scientists will find extremely outside my own: highlighting papers useful to keep abreast with the rapid advances in journais that I don't normally read: in our fields. And it will make this easy, and providing confirmation by an expert of a interesting and fun! paper I have read (e. a second opinion) James crapo National Jewish Medical and Martin Raff University College London Research Center. Denver, Colorado. USA Fellow of the Royal Society